AVEO Pharmaceuticals, Inc. (AVEO)

Jan 19, 2023 - AVEO was delisted (reason: acquired by LG Chem)
15.00
0.00 (0.00%)
Last trade price
Market Cap 521.45M
Revenue (ttm) 94.32M
Net Income (ttm) -29.04M
Shares Out 34.76M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE 48.08
Dividend n/a
Ex-Dividend Date n/a
Volume 245,298
Open 15.00
Previous Close 15.00
Day's Range 14.99 - 15.00
52-Week Range 3.06 - 15.00
Beta 0.98
Analysts Sell
Price Target 15.30 (+2.0%)
Earnings Date Mar 13, 2023

About AVEO

AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. It markets FOTIVDA, an oral, next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The company is also developing tivozanib for the treatment of RCC, hepatocellular carcinoma, ovarian cancer, immunologically cold tumors, and cholangiocarcinoma. In a... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 12, 2010
Employees 114
Stock Exchange NASDAQ
Ticker Symbol AVEO
Full Company Profile

Financial Performance

In 2021, AVEO's revenue was $42.30 million, an increase of 602.69% compared to the previous year's $6.02 million. Losses were -$53.34 million, 49.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for AVEO stock is "Sell." The 12-month stock price forecast is $15.3, which is an increase of 2.00% from the latest price.

Price Target
$15.3
(2.00% upside)
Analyst Consensus: Sell
Stock Forecasts

News

LG Chem Completes Acquisition of AVEO Oncology

AVEO to Become the U.S. Foundation for LG Chem Life Sciences' Oncology Division AVEO to Become the U.S. Foundation for LG Chem Life Sciences' Oncology Division

1 week ago - GlobeNewsWire

AVEO Oncology Stockholders Approve Acquisition by LG Chem

BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better ...

3 weeks ago - GlobeNewsWire

AVEO Oncology Reminds Stockholders to Vote “FOR” All-Cash Transaction with LG Chem in advance of the Special Meeting of Stockholders

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend that AVEO Stockholders Vote “FOR” the Transaction Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend that AVE...

1 month ago - GlobeNewsWire

4 Drug Stocks That More Than Doubled This Year

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

Other symbols: CABAVRNAWVE
1 month ago - Zacks Investment Research

Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?

Here is how AVEO Pharmaceuticals (AVEO) and Merit Medical (MMSI) have performed compared to their sector so far this year.

1 month ago - Zacks Investment Research

AVEO Oncology (AVEO): Strong Industry, Solid Earnings Estimate Revisions

AVEO Oncology (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

2 months ago - Zacks Investment Research

What Makes AVEO Pharmaceuticals (AVEO) a Strong Momentum Stock: Buy Now?

Does AVEO Pharmaceuticals (AVEO) have what it takes to be a top stock pick for momentum investors? Let's find out.

2 months ago - Zacks Investment Research

AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of 43.75% and 1.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

AVEO Oncology Reports Third Quarter 2022 Financial Results

– Total Q3 2022 Net Revenue of $30.4 million, including $30.2 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue –

3 months ago - GlobeNewsWire

AVEO Pharmaceuticals (AVEO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

AVEO (AVEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

AVEO Oncology (AVEO) to Report Q3 Earnings: Is a Beat in Store?

AVEO Oncology's (AVEO) third-quarter earnings is expected to reflect strong Fotivda sales. The company is likely to beat the Zacks Consensus Estimate.

3 months ago - Zacks Investment Research

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of AVEO Pharmaceuticals, Inc. - AVEO

NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm ra...

3 months ago - PRNewsWire

SHAREHOLDER ALERT: Weiss Law Investigates AVEO Pharmaceuticals, Inc.

NEW YORK , Oct. 21, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of AVEO Pharmaceuticals, Inc. ("AVEO" or t...

3 months ago - PRNewsWire

AVEO Pharmaceuticals (AVEO) Inks Deal to be Acquired by LG Chem

Aveo Pharmaceuticals (AVEO) is set to be acquired by LG Chem for an aggregate amount of $566 billion. The deal is expected to close by early 2023.

3 months ago - Zacks Investment Research

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating AVEO Pharmaceuticals, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - October 18, 2022) - Rigrodsky Law, P.A. is investigating AVEO Pharmaceuticals, Inc. ("AVEO") (NASDAQ CM: AVEO) regarding possible breaches of fiduciary duties a...

3 months ago - Newsfile Corp

LG Chem to acquire AVEO Oncology for $566 million

Yahoo Finance anchor Brad Smith breaks down how markets are trading, plus why AVEO stock is soaring today.

3 months ago - Yahoo Finance

Shareholder Alert: Ademi LLP investigates whether AVEO Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with LG Chem

MILWAUKEE , Oct. 18, 2022 /PRNewswire/ -- Ademi LLP is investigating AVEO (NASDAQ: AVEO) for possible breaches of fiduciary duty and other violations of law in its transaction with LG Chem.  Click her...

3 months ago - PRNewsWire

What Is Going on With AVEO Pharmaceuticals (AVEO) Stock Today?

AVEO Oncology (NASDAQ: AVEO) stock jumped 40% in premarket trading after LG Chem (OTCMKTS:LGCLF) said it would buy the company for $15/share in cash. The price implies a value of $566 million for AVE...

3 months ago - InvestorPlace

AVEO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of AVEO Pharmaceuticals, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) to LG Chem, Ltd.

3 months ago - Business Wire

LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash

SEOUL, South Korea and CAMBRIDGE, Mass. and BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) and AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-...

3 months ago - GlobeNewsWire

S.Korea's LG Chem to invest $566 mln to acquire U.S. Aveo Pharmaceuticals

South Korea's LG Chem Ltd said in a regulatory filing on Tuesday that it is investing $566 million to acquire U.S. firm Aveo Pharmaceuticals Inc and enter the U.S. anti-cancer drug market.

3 months ago - Reuters

3 Breakout Stocks to Keep an Eye on for Solid Returns

Par Pacific (PARR), AVEO Pharmaceuticals (AVEO) and Heritage Commerce Corp (HTBK) have been selected as the breakout stocks for today.

Other symbols: HTBKPARR
3 months ago - Zacks Investment Research

U.S. Patent & Trademark Office Allows AVEO Oncology's Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced Renal Cell Carcinoma

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for ...

4 months ago - GlobeNewsWire

Is AVEO Pharmaceuticals (AVEO) Stock Outpacing Its Medical Peers This Year?

Here is how AVEO Pharmaceuticals (AVEO) and Trevi Therapeutics, Inc. (TRVI) have performed compared to their sector so far this year.

4 months ago - Zacks Investment Research